Amsterdam, 19 - 20 March 2019

Schedule

Create your personal agenda –check the favourite icon

Mar 1909:00
Conference pass

Overview of the rare diseases landscape and the challenges facing HTAs

Keynotes
Sheela Upadhyaya, Associate Director Highly Specialised Technologies, National Institute for Health and Care Excellence
Mar 1909:20
Conference pass

Digital Innovation in Clinical Trial Design to support Market Access

Keynotes
Rob Scott, Chief Medical Officer, Vice President, Head Of Development, AbbVie
Mar 1909:40
Conference pass

The Value of a Cure

Keynotes
Paul Mcloughlin, VP of Market Access & Phase IV Solutions, Covance
Mar 1910:00
Conference pass

What is going on in Quebec about Market Access?

Keynotes
  • Examining Quebec life sciences strategy: Integration of medicines and technological innovations
  • Achieving cost reduction and improving access to medicines
  • Re-editing the evaluation process for the introduction of innovative medication and technologies
Luc Boileau, Président-Directeur General, Inesss
Mar 1911:20
Conference pass

Biosimilar pricing and access expectations in Europe

Keynotes
Andreia Ribeiro, Engagement Manager, Lifescience Dynamics Ltd
Mar 1912:00
Conference pass

25 Roundtables (max 15 PAX)

Keynotes
Roundtable 10: Sustainable pricing models for orphan drugs
Roundtable 11: Accelerating access to treatments for rare diseases
Elizabeth Owen, Head Of Translational Research Development, The Muscular Dystrophy U.K.
Roundtable 12: Payer insights and engagement for Italy
Marco Marchetti, Director Of The National Center For Health Technology Assessment, Istituto Superiore di Sanita
Roundtable 13: The use of registries to assess orphan drugs
Jan Span, Member Of The Cross-Committee Task Force On Registries And Senior Clinical Assessor, Medicines Evaluation Board The Netherlands
Roundtable 14: Making sustainable healthcare work
Michael Schroter, Partner, Viopas Partners
Roundtable 15: Pricing Strategy – What to Do and When?
Andreia Ribeiro, Engagement Manager, Lifescience Dynamics Ltd
Roundtable 1: Bridging the gap between clinical development and medical affairs, tailoring clinical trials to meet both MA and HTA requirements
Roundtable 2: Developments in pricing and access for biosimilars in Europe
Cristina Martin-Rinconada, Associate Director Strategic Pricing, Biogen Biosimilars Europe
Roundtable 3: Examining emerging trends for market access in LMICs, opportunities and challenges
Roundtable 4: Capability building for RWE
Melvin Olson, Global Head Rwd Strategy And Innovation, Novartis Pharma
Roundtable 5: Payer engagement in the world of orphan drugs
Roundtable 5: Payer engagement in the world of orphan drugs
Fabrizio Zucca, Director Patient Access Dach, Sobi
Roundtable 8: Role of RWE in oncology
Roundtable 9: Exploring regulatory and market access developments in advanced therapies
Renske Ten Ham, Phd Candidate, Utrecht University
Mar 1914:10
Conference pass
Mar 1914:10
Conference pass

Chair’s remarks

PRICING & MARKET ACCESS
Paul Newton, Director Strategic Pricing, UCB
Mar 1914:10
Conference pass
Mar 1914:10
Conference pass

Chair’s remarks

HTA
Katja Berg, Vice President Of Operations And Payers Intelligence, Sanofi
Mar 1914:10
Conference pass

Chair’s remarks

EMERGING MARKETS
Navin Joshi, Global Head Of Pricing, Classic And Established Products. Global Pharma, GlaxoSmithKline
Mar 1914:10
Conference pass

Chair’s remarks

BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Mar 1914:15
Conference pass

Can Pharma save $1 billion through the strategic use of RWE?

Evidence
Melvin Olson, Global Head Rwd Strategy And Innovation, Novartis Pharma
Mar 1914:15
Conference pass

Developments in indication and combination pricing models

PRICING & MARKET ACCESS
  • A look at the reimbursement and pricing environment and challenges for indication-based and combination therapy pricing
  • Addressing the information gap: Infrastructure needs
  • Where are we? Case studies on indication-based and combo pricing
Mar 1914:15
Conference pass

Title TBC

RARE DISEASES
Lara Pippo, Head Of Market Access, C.S.L. Behring Spa
Mar 1914:15
Conference pass

Comparing and Contrasting the UK and US HTA frameworks for assessing digital health

BIG DATA, DIGITAL HEALTH & ANALYTICS
Nadeem Ashraf, Medical Advisor - Diabetes, N/A
Mar 1914:15
Conference pass

Quantifying the ‘patient voice’: the importance of tolerability and quality-of-survival in HTA decisions

HTA
  • HTA and payer-relevant quantitative concepts to characterize AE profiles and tolerability will be reviewed
  • HTA acceptance of these quant. approaches will be illustrated and appraised
  • Examples and (potential future) approaches, for HTA and Access success will be discussed
Reg Waldeck, Market Access Strategy Leader, Bayer Corp
Mar 1914:15
Conference pass

Emerging trends for market access in LMICs, opportunities and challenges

EMERGING MARKETS
Mar 1914:35
Conference pass

Presentation reserved for Vistex

PRICING & MARKET ACCESS
Alejandra (Sandra) Garitonandía, Business Development, Vistex
Mar 1914:35
Conference pass

Beyond data - Deriving Actionable Intelligence

BIG DATA, DIGITAL HEALTH & ANALYTICS
Simon Swift, Managing Director, Methods Analytics
Mar 1914:55
Conference pass

USA perspective: Using RWE effectively to support product development

Evidence
Nneka Onwudiwe, Regulatory Reviewer, Food and Drug Administration
Mar 1914:55
Conference pass

Do RCTS influence pricing?

PRICING & MARKET ACCESS
Mauricio Alvarez Reyes, Market Access Director, Tesaro
Mar 1914:55
Conference pass

Going it alone: key challenges and benefits of launching a rare disease treatment in Europe

RARE DISEASES
David Boothe, Regional Commercial Head, Spark Therapeutics
Mar 1914:55
Conference pass

The use of Ehealth tools to measure health outcomes for pricing purposes

BIG DATA, DIGITAL HEALTH & ANALYTICS
Geert Pelsmaeker, General Manager, Leaphy
Mar 1914:55
Conference pass

Title TBC

HTA
Florian Turk, Head Of Global Payor Marketing, Sales And Relations, Sandoz
Mar 1914:55
Conference pass

Latest HTA developments in Colombia

EMERGING MARKETS
Aurelio Mejia, Former Deputy Director Of Hta, IETS
Mar 1915:15
Conference pass

Chair’s remarks

Evidence
Michael Lees, Head Of Value, Evidence And Portfolio Strategy, Takeda
Mar 1915:15
Conference pass

Chair’s remarks

PRICING & MARKET ACCESS
Diane Munch, Head Of Global Pricing, Patient And Health Impact, Pfizer
Mar 1915:15
Conference pass

Chair’s remarks

RARE DISEASES
Segolene Ayme, Founder Of Orphanet And Rare Disease Expert In Residence, ICM, Paris
Mar 1915:15
Conference pass

Chair’s remarks

BIG DATA, DIGITAL HEALTH & ANALYTICS
Mark Duman, Nw Service Champion, Diabetes U.K.
Mar 1915:15
Conference pass

Chair’s remarks

VALUE
Rafaat Rahmani, President, Lifescience Dynamics Ltd
Mar 1915:15
Conference pass

Chair’s remarks

EMERGING MARKETS
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Mar 1915:15
Conference pass

Chair’s remarks

BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Mar 1915:20
Conference pass

Use of value frameworks within oncology in Europe

Evidence
  • Innovation and launches in oncology are moving at a rapid pace, potentially resulting in a delay in formal reimbursement appraisal and guidance
  • A number of value frameworks have been developed with the intent of providing rapid advice to oncologists on the clinical benefit of these new drugs
  • These value frameworks have many advantages, including clarity and brevity, but they do not replace the full value assessment of a formal HTA
Gwilym Thompson, Director Worldwide Heor, BMS
Mar 1915:20
Conference pass

Market access requirements in Germany

PRICING & MARKET ACCESS
Marco Penske, Head Of Market Access And Health Care Affairs, Boehringer Ingelheim Biopharmaceuticals Gmbh
Mar 1915:20
Conference pass

Using payer data to support rare disease treatments in Germany

RARE DISEASES
  • Reliability
  • Analyses
  • Outcome
Axel Boehnke, Director Market Access (Global Responsibility), MorphoSys AG
Mar 1915:20
Conference pass

4D Insights - powering access

BIG DATA, DIGITAL HEALTH & ANALYTICS
  • Aligning Payers, Policy Markers, Prescribers and Patient Insight using the power of Big Data
  • Real-time Insights giving competitive advantage
  • Measuring impact in real-time from within the health system
David Williams, Chief Medical Officer, Visformatics
Mar 1915:20
Conference pass

What does value mean for payers, patients and pharma?

VALUE
Isabel Torres, Vice President Market Access, Public Affairs And Patient Advocacy For Europe And Canada, Takeda
Mar 1915:20
Conference pass

The Sanofi Espoir Foundation- Providing new payment access systems to emerging markets

EMERGING MARKETS
Valerie Faillat, Head Of Sanofi Espoir Foundation, Sanofi
Mar 1916:00
Conference pass

What patients expect from clinical research and researchers - and how patient advocacy can help deliver it

Evidence
Richard Stephens, Chair Of Consumer Liaison Group, National Cancer Research Institute (NCRI)
Mar 1916:00
Conference pass

The pharmaceutical market of the Russian Federation: trends and prospects

PRICING & MARKET ACCESS
Ivan Glushkov, External Affairs Department Director, S.T.A.D.A.
Mar 1916:00
Conference pass

Payer engagement in the world of orphan drugs

RARE DISEASES
Dennis Dionne, Chief Executive Officer, Newron Pharma
Mar 1916:00
Conference pass

The use of big data in other industries and what pharma can learn from this

BIG DATA, DIGITAL HEALTH & ANALYTICS
Enkeleida Nikai, Head Of Real World Evidence, Senior Director At Janssen Europe, Middle East And Africa (Emea), Janssen Pharmaceutical
Mar 1916:00
Conference pass

How to capture and quantify patient value within a commercial strategy

VALUE
Daniel Jackson, Global Head Of Market Access, Solutions And Strategy, UCB
Mar 1916:00
Conference pass

Reimbursement and risk-sharing in South Korea

EMERGING MARKETS
Jeonghoon Ahn, Director, National Evidence-based Healthcare Collaborating Agency
Mar 1916:00
Conference pass

Delivering affordable and sustainable medicines to patients across Europe through Biosimilars

BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Mar 1916:50
Conference pass

Chair’s remarks

Evidence
Deven Chauhan, Senior Director, Value Evidence Leader, GlaxoSmithKline
Mar 1916:50
Conference pass

Chair’s remarks

PRICING & MARKET ACCESS
Steven Flostrand, Senior Director Of Pricing And Market Access, Celgene
Mar 1916:50
Conference pass

Chair’s remarks

BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Mar 1916:55
Conference pass

RWE – disrupter or quiet evolution?

Evidence
Sandra Leonard, Vice President Of Medical Evidence And Observational Research, AstraZeneca
Mar 1916:55
Conference pass

Integrating care to secure early access and effective pricing

PRICING & MARKET ACCESS
Andrea Mantovani, Director Of Country Market Access, Amgen Inc
Mar 1916:55
Conference pass

Utilising disease registries for orphan drug launch

RARE DISEASES
  • Utilising disease registries is vital in rare diseases and a multicountry, multi-stakeholder approach will be discussed
  • In Europe, linkage is needed as well between registries and EU Reference networks and this can prove to be an invaluable relation ship
  • Technological challenges are a problem and potential approaches will be explored
Peter Rutherford, Global Medical Lead Of Orphan Renal Diseases, Vifor Pharma Group
Mar 1916:55
Conference pass

Digital Therapeutics: The promise and the evidence

BIG DATA, DIGITAL HEALTH & ANALYTICS
Oliver Gassner, Head Digital Health Intelligence | Emea, Bayer
Mar 1916:55
Conference pass

Increasing availability of biosimilars and examining market access policies

BIOSIMILARS
Sue Naeyaert, Global Head Government Affairs And Policy Biosimilars, Fresenius Kabi
Mar 1916:55
Conference pass

Realising the insurance business model to establish effective partnership working

REIMBURSEMENT
Charles De Cidrac, Director Of Health Insurance, AXA
Mar 1917:15
Conference pass

Roadmap to Reimbursement: A Review of Successes and Stumbles

REIMBURSEMENT
Mar 1917:35
Conference pass

Evidentry standards for RWE in a changing world

Evidence
Tony Hebden, Vice President Of Health Economics And Outcomes Research, AbbVie
Mar 1917:35
Conference pass

Insights for NICE: The evolving landscape for market access

PRICING & MARKET ACCESS
Carla Deakin, Associate Director, Office For Market Access, NICE
Mar 1917:35
Conference pass

Innovative Value based contracting for gene therapy

RARE DISEASES
Mar 1917:35
Conference pass

The use of real world data to generate evidence across the drug life cycle

BIG DATA, DIGITAL HEALTH & ANALYTICS
Margaret Mcdonald, Senior Director, Global Market Access, Pfizer
Mar 1917:35
Conference pass

Market Access developments for Biosimilars in Europe

BIOSIMILARS
Philip Aubrey, Associate Director Market Access Biosimilars, Uk, Netherlands And Ireland, Biogen
Mar 1917:35
Conference pass

Reimbursement within the world of Oncology

REIMBURSEMENT
  • Oncology Environment and Patient Access to the Oncology Therapies
  • Patient Access & Support Programs in Oncology
  • Reimbursement issues and impact of the reimbursement delays in Oncology
Igor Rudychev, Senior Director, Business Insights, Immuno-Oncology, AstraZeneca

Create your personal agenda –check the favourite icon

Mar 2009:00
Conference pass

Insights for HTA harmonisation across Germany and Europe

Keynotes
Thomas Mueller, Head Of Directorate General 1 "Drugs, Medical Devices, Biotechnology", Bundesministerium fur Gesundheit
Mar 2009:40
Conference pass

Achieving greater collaboration amongst payers, HTAs, pharma and patients to improve access and pricing

Keynotes
  • Overview of key European and global initiatives and next steps
  • Looking at the role of technological innovation in access, pricing and evidence
  • Working with payers, patients and pharma to generate value
Thomas Mueller, Head Of Directorate General 1 "Drugs, Medical Devices, Biotechnology", Bundesministerium fur Gesundheit
Stefan Scherer, Vice President Head Of Early Development Strategy, McKesson Specialty Health The U.S. Oncology Network
Saira Jan, Director Of Pharmacy Strategy And Clinical Integration, Blue Cross Blue Shield of New Jersey
Jaume Vidal, Policy Advisor, Eu Projects, Health Action International
Andreia Ribeiro, Engagement Manager, Lifescience Dynamics Ltd
Mar 2011:00
Conference pass

Chair’s remarks

EVIDENCE
Gundula Schneidewind, Managing Director, Takeda Belgium
Mar 2011:00
Conference pass

Chair’s remarks

PRICING AND MARKET ACCESS
Elizabeth Mckenna, Head Of Market Access Uk And Ireland, Vertex Pharmaceuticals
Mar 2011:00
Conference pass

Chair’s remarks

RARE DISEASES
Josie Godfrey, Project Director, Duchenne
Mar 2011:00
Conference pass
Mar 2011:00
Conference pass
Mar 2011:00
Conference pass

Chair’s remarks

MANAGED ENTRY AGREEMENTS
Giuseppe Rosano, Member Of The Cardiovascular Working Party, European Medicines Agency
Mar 2011:05
Conference pass

Federated & Harmonised Real World Research in the EU 2020+: A Convergence of Intent, Collaboration & Technology?

EVIDENCE
  • The next decade of RWD/RWE-based research in Europe – the federated model and edge analytics
  • Data harmonisation – an international initiative and the Rosetta Stone of RWD?
  • What have we learned from IMI EMIF, from its original inception, project experience, and sustainability scale up
  • The premise for EHDN, aims and likely impact
  • Meeting the needs of multiple stakeholders
Mar 2011:05
Conference pass

Learnings from the Netherlands in the world of pricing and market access

PRICING AND MARKET ACCESS
Jolanda Koenders, Head Of Pricing And Market Access Pharma, Novartis
Mar 2011:05
Conference pass

Value based medicine: whose values?

RARE DISEASES
Mark Macgregor, Interim Medical Director, Acute Services, Nhs Scotland
Mar 2011:05
Conference pass

Pharmaceutical Affordability

AFFORDABILITY
  • Ability to Pay versus Willingness to Pay
  • Considerations for Product-specific and Patient-specific affordability programs
  • Partnering with payers/policy makers
John Alter, Vice President Pricing And Market Access, Pfizer
Mar 2011:05
Conference pass

Developing advanced therapies for rare disease: is this sustainable?

ADVANCED THERAPIES
Diego Ardigo, Research And Development Rare Diseases Unit Head, Chiesi Farmaceutici SpA
Mar 2011:05
Conference pass

Latest developments in managed entry agreements for Europe

MANAGED ENTRY AGREEMENTS
Katja Berg, Vice President Of Operations And Payers Intelligence, Sanofi
Mar 2011:25
Conference pass
Mar 2011:45
Conference pass

The role of evidence in anti-infective value assessments

EVIDENCE
Keiko Tone, Vice President Market Access, Shionogi Limited
Mar 2011:45
Conference pass

Understanding the US healthcare model: examining oncology treatments

PRICING AND MARKET ACCESS
Ed Pezalla, Former Vice President, National Medical Director For Pharmaceutical Policy And Strategy, Aetna
Mar 2011:45
Conference pass

Market access considerations for rare disease treatments

RARE DISEASES
Simon Shohet, Senior Director, Global Market Access And Pricing, Ipsen
Mar 2011:45
Conference pass

Achieving affordability in South America

AFFORDABILITY
Andres Pichon Riviere, Executive Director And Director Of Health Technology Assessment And Economic Evaluations, I.E.C.S.
Mar 2011:45
Conference pass

Examining the regulatory landscape for CAR-T

ADVANCED THERAPIES
  • CAR T-Cell Therapy, a new therapeutic approach: Between euphoria and scepticism
  • Drug or therapeutic method: first experiences in the German health care system
  • Most expensive cancer treatment ever: New approaches for affordability and sustainability
Detlev Parow, Head Of Department Of Medicines, Therapeutic Appliances And Remedies, D.A.K.
Mar 2011:45
Conference pass

Implementation of managed entry agreements over the last decade in Australia

MANAGED ENTRY AGREEMENTS
Matt Slabbert, Head Of Market Access, Advocacy And Policy, Anz, Bayer Pharmaceuticals
Mar 2014:05
Conference pass

Chair’s remarks

PRICING AND MARKET ACCESS
David Watson, Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry
Mar 2014:10
Conference pass

Precision medicine in oncology: challenges and possible solutions from a payer’s perspective

EVIDENCE
  • What are the key challenges we face in commissioning tests and treatments in this fast-paced and innovative field?
  • How can we ensure our patients have access to tests and treatments that are safe and effective despite limited evidence?
  • What solutions could be considered to manage costs to payers (and our customers) and safeguard precision medicine as a sustainable option in the future?
Lucy Hoppe, Clinical Effectiveness Manager (Evidence Synthesis) In The Clinical Effectiveness Team, Bupa
Mar 2014:10
Conference pass

Access in the new NHS landscape

PRICING AND MARKET ACCESS
Diar Fattah, Associate Director Of Medicines Optimisation, N.H.S._Dartford Gravesham and Swanley C.C.G.
Mar 2014:10
Conference pass

Launching rare disease products to a world market

RARE DISEASES
Mar 2014:10
Conference pass

Biosimilars and their impact on drug contracting in the value chain

CONTRACTING AND PRICE TENDERING
Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
Mar 2014:10
Conference pass

Developments in CAR-T for Russia

ADVANCED THERAPIES
Daria Tolkacheva, Head Of Health Economics, JSC BIOCAD
Mar 2014:10
Conference pass

Engaging with patients and improving outcomes

PATIENT AND PAYER ENGAGEMENT
Dawn Ireland, President, CDH International
Mar 2014:40
Conference pass

Chair’s remarks

MEDICAL AND GOVERNMENTAL AFFAIRS
Robert Popovian, Vice President Of Government Relations, Pfizer
Mar 2014:50
Conference pass
Mar 2014:50
Conference pass

Developing a new payment system for a polysymptomatic rare disseise

RARE DISEASES
Dennis Dionne, Chief Executive Officer, Newron Pharma
Mar 2014:50
Conference pass

Contracting and price tendering for cancer treatments

CONTRACTING AND PRICE TENDERING
Marcela Junqueira, Head Of Strategic Affairs And Health Economics, Janssen Pharmaceutical
Mar 2014:50
Conference pass

Using evidence to support pricing for gene therapies

ADVANCED THERAPIES
Omar Dabbous, Vice President Health Economics And Outcomes Research, AveXis Inc
Mar 2014:50
Conference pass

Title TBC

PATIENT AND PAYER ENGAGEMENT
Dan Pettitt, Global Head Of Immunology Market Access, Johnson & Johnson
Mar 2015:45
Conference pass

Pay for performance: discussing the first large scale study into efficacy of the model

EVIDENCE
Mar 2015:45
Conference pass

Developments in pricing and patient access for speciality treatments

PRICING AND MARKET ACCESS
Diann Potestio, Senior Director, National Accounts, Multiple Sclerosis And Immunology, Genzyme
Mar 2015:45
Conference pass

Accelerating access to treatments for rare diseases

RARE DISEASES
Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.
Mar 2015:45
Conference pass

Accounting profitability and the political process: the case of R&D accounting in the pharmaceutical industry

MEDICAL AND GOVERNMENTAL AFFAIRS
Mar 2015:45
Conference pass

Bringing gene therapies to market – strategic considerations

ADVANCED THERAPIES
Darren Walsh, Senior Director - Market Access & Govt. Affairs – EU, Orchard Therapeutics
Mar 2016:05
Conference pass

Medical drug management a US payer perspective

MEDICAL AND GOVERNMENTAL AFFAIRS
Saira Jan, Director Of Pharmacy Strategy And Clinical Integration, Blue Cross Blue Shield of New Jersey
Mar 2016:05
Conference pass

Advancing therapy developments through new pricing models

ADVANCED THERAPIES
Inge Bliestle, Commercial Director, Actelion
Mar 2016:25
Conference pass

The role of RWE in HTAs and regulatory affairs in Germany

EVIDENCE
Jorg Tomeczkowski, Head Of Market Access, Janssen Cilag Germany
Mar 2016:25
Conference pass

HTA in Switzerland

PRICING AND MARKET ACCESS
  • Legal Context of HTA in Switzerland
  • HTA Processes
  • Implementation of HTA
Mar 2016:25
Conference pass

Methods for clinical statistical modeling to reduce trial size

RARE DISEASES
Qing Liu, Head Of Biostatistics And Data Management, Amicus Therapeutics Inc
Mar 2016:25
Conference pass

Landscape of Drug Pricing, Spending and Affordability In The U.S.

MEDICAL AND GOVERNMENTAL AFFAIRS
Robert Popovian, Vice President Of Government Relations, Pfizer
Mar 2016:25
Conference pass

Developing new affordable and sustainable pricing models for a changing health landscape

ADVANCED THERAPIES
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Mar 2016:55
Conference pass

Chair's closing remarks

MEDICAL AND GOVERNMENTAL AFFAIRS
Robert Popovian, Vice President Of Government Relations, Pfizer
last published: 13/Dec/18 16:35 GMT